EF-5

SKU: orb1308346

Description

EF-5 (2-Nitroimidazole) is a hypoxia marker used to detect and quantify low oxygen conditions in biological systems. It is widely applied in both in vitro and in vivo cancer research to study tumor hypoxia, angiogenesis, and treatment response.

Key Properties

• CAS Number: 152721-37-4
• MW: 302.16
• Purity: 98.79% (May vary between batches)
• Formula: C₈H₇F₅N₄O₃
• SMILES: [O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F
• Target: Others
• Solubility: DMSO:125 mg/mL (413.69 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (13.24 mM)

Bioactivity

• In Vivo:
  EF-5 binding is a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs. Binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen-dependent after intravenous injection of EF-5. Tumor hypoxia modification causes similar changes in the bioreductive activation of both agents, showing a strong correlation between EF-5 binding and CEN209-induced DNA damage at the individual tumor level . Detection using fluorescence microscopy can be performed on frozen tissues, with tissue sections counterstained with haematoxylin and eosin for light microscopic analysis. The hypoxia distribution in a tumor can be inferred by examining individual tumor cells using flow cytometric techniques .
  Read more...
• In Vitro:
  EF-5 binding and metabolic reduction of the prodrugs are highly correlated in a panel of 14 hypoxic tumor cell lines. Overexpression of CYPOR causes similar 2- to 4-fold increases in EF-5 binding and metabolic reduction of tirapazamine and CEN-209 in SiHa and HCT116 cell lines. Which is similar enhancement of γH2AX formation..
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

2-Nitroimidazole, EF5, EF-5, EF 5, Inhibitor, inhibit

Compound Identifiers

PubChem CID

389053